Carole Ben-Maimon, Larimar Therapeutics CEO
Larimar to kick off higher dose of lead rare disease drug, initiate OLE trial
The FDA gave Larimar Therapeutics the go-ahead to introduce a higher dose of its Friedreich’s ataxia treatment in a Phase II study.
The biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
